Evidence map›Paper›PMID 26576633›Full record

Trial reportTrials2015

Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial.

Simon Forstmeier, Andreas Maercker, Egemen Savaskan, Tanja Roth

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01273272 (Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia), which is not on this map. Cited by 7 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 5 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01273272 phase2completednot on this map

Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial

TypeinterventionalSponsorUniversity of ZurichRan2011 to 2017Enrolled50ConditionsAlzheimer DiseaseArmsComprehensive, CBT-based, multi-component treatment, Treatment as usual
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Simon ForstmeierDevelopmental Psychology, Faculty II, University of Siegen, Adolf-Reichwein-Str. 2, 57068, Siegen, Germany. simon.forstmeier@uni-siegen.de.
Andreas MaerckerPsychopathology and Clinical Interventions, Department of Psychology, University of Zurich, Binzmuehlestrasse 14/17, 8050, Zurich, Switzerland. maercker@psychologie.uzh.ch.
Egemen SavaskanClinic for Geriatric Medicine, Psychiatric University Hospital, University of Zurich, Minervastrasse 145, 8032, Zurich, Switzerland. egemen.savaskan@puk.zh.ch.
Tanja RothClinic for Geriatric Medicine, Psychiatric University Hospital, University of Zurich, Minervastrasse 145, 8032, Zurich, Switzerland. tanja.roth@bli.uzh.ch.
University of Zurich · CHUniversity of Siegen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAbout 90 % of all persons with mild Alzheimer's disease experience neuropsychiatric symptoms, most frequently apathy, depression, anxiety and irritability. These symptoms are associated with greater morbidity, a reduced quality of life for the patient, an increased burden and depression for the caregiver, and higher costs of care and nursing home placement. Psychosocial interventions based on behaviour therapy represent the most efficacious treatment of neuropsychiatric symptoms. However, there is no study, to our knowledge, that has evaluated a multicomponent treatment programme based on comprehensive, cognitive behavioural therapy (CBT). This randomized controlled trial aims to evaluate a CBT-based treatment programme consisting of 8 modules and 25 sessions. METHODS/

designFifty patients with mild Alzheimer's disease alone or with mild mixed dementia (Alzheimer's disease and vascular dementia) who have any neuropsychiatric symptom will be included. A caregiver must be available. The patients and their caregivers will be randomized to either the CBT-based intervention group or to the control condition group, which receives treatment as usual. The primary outcome measure is depression in the patient with Alzheimer's disease. The secondary outcome measures for a person with Alzheimer's disease are other neuropsychiatric symptoms, quality of life and coping strategies. The secondary outcome measures for a caregiver are caregiver's burden, depression, anxiety, anger, quality of life and coping strategies. Neuropsychological testing includes tests of cognitive function and activities of daily living and a global clinical assessment of severity. Participants in both groups will be assessed before and after the treatment phase (lasting approximately 9 months). Follow-up assessments will take place 6 and 12 months after treatment. All assessments will be conducted by blinded assessors. DISCUSSION: This trial has the potential to establish an empirically based psychological treatment for non-cognitive symptoms that reduce the quality of life of a person with dementia and a caregiver. This treatment approach focuses not only on the person with dementia, but also on the caregiver and on the dyad. The treatment manual will be published and training workshops will be offered, so that the information can be widely spread among healthcare professionals.

trial registrationClinicalTrials.gov NCT01273272.

Indexed as

Cognitive Behavioral TherapyAdaptation, PsychologicalAffectAlzheimer DiseaseCaregiversClinical ProtocolsCost of IllnessHumansNeuropsychological TestsPsychiatric Status Rating ScalesQuality of LifeResearch DesignSeverity of Illness IndexSurveys and QuestionnairesSwitzerlandTime Factors

Identifiers

PMID26576633
PMCPMC4650298
OpenAlexW2176065154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.